Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rennie Mccabe (NPI 1194915579)

Field	Value
Entity Type	Individual
Organization	Rennie Mccabe
Address	7111 E Lowry Blvd Ste 200
City	Denver
State	CO
ZIP	80230
Taxonomy	Rheumatology Physician
NPI Enumerated	July 31, 2007

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This rheumatology practice’s Medicare revenue is heavily driven by in-office biologic and infusion drug administration: the top three codes are J0129 ($393.5K, 29.0%), J3262 ($230.2K, 17.0%), and J9312 ($138.6K, 10.2%), and the list also includes multiple other infusion biologics (J1602, J1745, J0897) plus chemotherapy administration codes (96413, 96401, 96415). The presence of high-revenue biologic codes and chemotherapy administration descriptors suggests the provider operates an infusion-capable clinic or otherwise bills for supervised parenteral biologic therapies rather than relying primarily on procedure-only services.

Revenue concentration is pronounced: the precomputed top-3 codes account for 56.3% of this provider’s total Medicare revenue, and J0129 alone represents 29.0% of Medicare receipts. This concentration indicates that a relatively small set of biologic agents drives the majority of billings and financial exposure on the Medicare side.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $1.3M while there is no Medicaid billing on file. That absence of Medicaid activity means the provider’s public-payer exposure is concentrated in Medicare and the practice may be more sensitive to Medicare reimbursement policy and utilization changes than practices with mixed Medicaid volumes.

Competitive standing across specific drugs is mixed but generally modest-to-typical: J0129 ranks #374 of 1221 providers nationally (69th percentile; typical, unremarkable volume for this code) and J3262 ranks #254 of 618 (59th percentile; typical, unremarkable volume), indicating active but not dominant national positions for abatacept and tocilizumab administrations. By contrast, J9312 ranks #232 of 317 (26th percentile; typical, unremarkable volume), showing that rituximab use is comparatively lower versus national peers.

The practice shows relative strength on a few other biologic/injectable codes and infusion services: J0897 (denosumab) reports $119.9K and ranks #2007 of 10057 (80th percentile; typical, unremarkable volume), and chemotherapy administration code 96413 reports $51.5K and ranks #809 of 7514 (89th percentile; typical, unremarkable volume). These higher percentiles for denosumab and 96413 suggest the provider has comparatively notable activity delivering certain injectables and infusion therapies versus broad national peers.

Office visit (E/M) revenue is small relative to drug revenue: 99214 accounts for $38K (2.8% of Medicare revenue) while 99213 and 99205 each account for roughly $5K (0.4% each). This pattern reinforces that the practice’s economics are dominated by drug/infusion billing rather than volume of billable office visits.

The provider bills both originator and biosimilar infliximab products (J1745 $124K and Q5104 $48.1K), indicating flexibility in product mix or payer-driven substitution; this mix may reflect procurement decisions or contract-driven biosimilar uptake. Ancillary procedure codes such as 20610 (joint injection) and 77080 (DXA, $1K) also appear on the roster, suggesting delivery of routine rheumatology office procedures in addition to infusions.

The NPI was enumerated on 2007-07-31 (~19 years ago), indicating a long-established billing history in Medicare. That tenure, combined with a concentrated biologic/infusion code mix, points to a mature rheumatology practice that has developed an infusion-oriented service line over many years.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

30 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,930	$30	$393.5K
J3262	Injection, tocilizumab, 1 mg	46,040	$10	$230.2K
J9312	Injection, rituximab, 10 mg	2,200	$60	$138.6K
J1602	Injection, golimumab, 1 mg, for intravenous use	11,600	$10	$127.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,770	$30	$124K
J0897	Injection, denosumab, 1 mg	6,660	$20	$119.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$110	$51.5K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	1,550	$30	$48K
J3111	Injection, romosozumab-aqqg, 1 mg	5,880	$10	$47K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	390	$100	$38K

Showing 1–10 of 30

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 30 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Rennie Mccabe — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

30 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	6	30	6,280	$30	$250.4K
J9312	8	10	3,000	$60	$193.6K
J3262	6	20	28,180	$1	$158.6K
J1745	12	40	3,180	$30	$110.6K
J1602	8	20	8,100	$10	$108.9K
J3111	35	40	9,770	$10	$108.3K
J0897	19	140	2,580	$20	$68.8K
Q5104	6	10	1,990	$30	$62.6K
96413	12	140	130	$100	$19.7K
99214	634	8,160	80	$80	$11.3K

Showing 1–10 of 30

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rennie Mccabe, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stephen Murphy	CO	Rheumatology Physician	$1.4M	$0
Gregory Barron	CO	Rheumatology Physician	$1.4M	$0
Vance Bray	CO	Rheumatology Physician	$1.3M	$0
Annemarie Whiddon	CO	Rheumatology Physician	$1.3M	$0
Kim Tyler	CO	Rheumatology Physician	$1.3M	$0
Barbara Goldstein	CO	Rheumatology Physician	$1.1M	$0
Adam Berlinberg	CO	Rheumatology Physician	$773.5K	$0
Timothy Gensler	CO	Rheumatology Physician	$734.8K	$0
Christopher Antolini	CO	Rheumatology Physician	$598.9K	$0
Prateek Chaudhary	CO	Rheumatology Physician	$330K	$0

Nearby Providers

Other providers in the same ZIP code as Rennie Mccabe, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$25.5M
Total Longterm Care, Inc.	CO	Exclusive Provider Organization	$0	$13M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$8.3M
Lowry Pediatrics, PC	CO	Pediatrics Physician	$0	$4.4M
Miriah Teeter	CO	Retina Specialist (Ophthalmology) Physician	$1.9M	$0
Nancy Christmas	CO	Retina Specialist (Ophthalmology) Physician	$1.8M	$0
David Johnson	CO	Specialist	$1.5M	$0
Brian Joondeph	CO	Retina Specialist (Ophthalmology) Physician	$1.4M	$0
Alan Kimura	CO	Retina Specialist (Ophthalmology) Physician	$982.5K	$0
Shaun Gabriel	CO	Interventional Pain Medicine Physician	$889.8K	$0

Rennie Mccabe — Billing Profile & Reimbursement Data

Sign up for Rennie Mccabe — Billing Profile & Reimbursement Data policy alerts

Rennie Mccabe — Billing Profile & Reimbursement Data

Sign up for Rennie Mccabe — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References